Here are worldwide third-quarter sales figures for some key Pfizer prescription drugs. Except for Enbrel and Prevnar, the decreases are due to generic competition.
PRODUCT NAME MAIN CONDITION/USE 3Q 2012 SALES 3Q 2011 SALES PERCENT CHANGE
Lipitor High cholesterol $749 million $2.6 billion down 71 percent
Lyrica Fibromyalgia/pain $1.04 billion $961 million up 8 percent
Enbrel (outside U.S.) Rheumatoid arthritis $893 million $957 million down 7 percent
Prevnar 13 Pneumococcal vaccine $868 million $1.01 billion down 14 percent
Celebrex Pain $676 million $643 million up 5 percent
Viagra Erectile dysfunction $517 million $493 million up 5 percent
Norvasc High blood pressure $319 million $350 million down 9 percent
Zyvox MRSA infections $328 million $321 million up 2 percent
Sutent Multiple cancers $294 million $298 million down 1 percent
Premarin/Prempro Menopause symptoms $262 million $267 million down 2 percent
Source: Pfizer Inc.
Report: Active Shooter Near Planned Parenthood Location in Colorado UPDATE: "No Connection to Planned Parenthood" Says PD | Christine Rousselle
'More white Christian terrorism?' Tweeters profile perp in reported Planned Parenthood shooting
Leah Barkoukis - Unreal: Anti-Gun DC Police Chief Urges Public to ‘Take Down’ Active Gunman If Possible
S.C. Woman Outdraws, Outshoots, And Kills CraigsList Robber - Bearing Arms - Guns Saving Lives, South Carolina
Planned Parenthood Shooter Finally Convinces Leftists that Beliefs Matter | RedState
Millennials’ New American Dream | Human Events
Dr. Mark Skousen - When Will the Market Doomsayers and Permabears Be Right?
Reports: Active shooter barricaded in Colorado Springs Planned Parenthood, firing at cops; Update: Cops confronting shooter inside the building